This company has shut down. EnBiotix is no longer operating — its last tracked round was a Venture - Series Unknown in 2022.
Explore the Startup GraveyardEnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
EnBiotix has raised $3.5M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2022.
EnBiotix's investors include Cystic Fibrosis Foundation, Apeiron Holdings Limited, Vectura, Sanford Biosciences, Wired Holdings.
EnBiotix is headquartered in Cambridge, United States.
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
EnBiotix is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EnBiotix — Funding & Investors." VCBacked, April 5, 2022, https://www.vcbacked.co/company/enbiotix. Accessed August 14, 2026.
VCBacked. (2022). EnBiotix — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/enbiotix
{{cite web |title=EnBiotix — Funding & Investors |url=https://www.vcbacked.co/company/enbiotix |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated